actinomycin c + azathioprine

This is a combination of two drugs, actinomycin C and azathioprine. Actinomycin C (also known as dactinomycin) is an antineoplastic antibiotic that binds to DNA and inhibits RNA synthesis, leading to cytotoxic effects primarily used in the treatment of various cancers such as Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, and testicular cancer. Azathioprine is an immunosuppressant prodrug of 6-mercaptopurine used to prevent organ transplant rejection and treat autoimmune diseases like rheumatoid arthritis, Crohn's disease, and ulcerative colitis. The combination may theoretically increase the risk or severity of adverse effects due to overlapping toxicities or immunosuppression[1][2]. There are no widely recognized clinical uses for this specific drug combination; it does not appear as a standard therapy in guidelines or essential medicines lists.